- Home
- IONS vs FLS Comparison
IONS vs FLS Comparison
Compare IONS & FLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- FLS
- Stock Information
- Founded
- IONS 1989
- FLS 1790
- Country
- IONS United States
- FLS United States
- Employees
- IONS N/A
- FLS N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- FLS Fluid Controls
- Sector
- IONS Health Care
- FLS Industrials
- Exchange
- IONS Nasdaq
- FLS Nasdaq
- Market Cap
- IONS 6.8B
- FLS 7.1B
- IPO Year
- IONS 1991
- FLS N/A
- Fundamental
- Price
- IONS $69.15
- FLS $52.65
- Analyst Decision
- IONS Strong Buy
- FLS Strong Buy
- Analyst Count
- IONS 18
- FLS 9
- Target Price
- IONS $72.83
- FLS $66.89
- AVG Volume (30 Days)
- IONS 2.2M
- FLS 2.2M
- Earning Date
- IONS 11-05-2025
- FLS 10-27-2025
- Dividend Yield
- IONS N/A
- FLS 1.59%
- EPS Growth
- IONS N/A
- FLS 13.91
- EPS
- IONS N/A
- FLS 2.21
- Revenue
- IONS $944,050,000.00
- FLS $4,646,070,000.00
- Revenue This Year
- IONS $24.01
- FLS $6.59
- Revenue Next Year
- IONS $4.06
- FLS $4.10
- P/E Ratio
- IONS N/A
- FLS $23.88
- Revenue Growth
- IONS 16.05
- FLS 3.15
- 52 Week Low
- IONS $23.95
- FLS $37.34
- 52 Week High
- IONS $69.25
- FLS $65.08
- Technical
- Relative Strength Index (RSI)
- IONS 80.12
- FLS 37.02
- Support Level
- IONS $61.03
- FLS $52.11
- Resistance Level
- IONS $63.18
- FLS $53.61
- Average True Range (ATR)
- IONS 1.63
- FLS 1.31
- MACD
- IONS 0.02
- FLS -0.45
- Stochastic Oscillator
- IONS 89.41
- FLS 13.19
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About FLS Flowserve Corporation
Flowserve Corp is a manufacturer and aftermarket service provider of comprehensive flow control systems. It develops precision-engineered flow control equipment to monitor movement and protect customers' materials and processes. It offers an extensive range of pumps, valves, seals, and services for several industries, including oil and gas, chemical, power generation, and water management. It has three business segments: FPD for custom engineered pumps, pre-configured industrial pumps, pump systems, mechanical seals, auxiliary systems and replacement parts and related services; and FCD for engineered-to-order and configured-to-order isolation values, control valves, valve automation products and related equipment and Eliminations and All Other.